title: Investigation of Fat Metabolism during Antiobesity Interventions by Magnetic Resonance Imaging and Spectroscopy.
abstract: The focus of current treatments for obesity is to reduce the body weight or visceral fat, which requires longer duration to show effect. In this study, we investigated the short-term changes in fat metabolism in liver, abdomen, and skeletal muscle during antiobesity interventions including Sibutra mine treatment and diet restriction in obese rats using magnetic resonance imaging, magnetic resonance spectroscopy, and blood chemistry. Sibutramine is an antiobesity drug that results in weight loss by increasing satiety and energy expenditure. The Sibutramine-treated rats showed reduction of liver fat and intramyocellular lipids on day 3. The triglycerides (TG) decreased on day 1 and 3 compared to baseline (day 0). The early response/nonresponse in different fat depots will permit optimization of treatment for better clinical outcome rather than staying with a drug for longer periods.
authors.affiliation: Laboratory of Molecular Imaging, Singapore Bioimaging Consortium, ASTAR, Singapore.
authors.forename: Arunima
authors.initials: A
authors.lastname: Pola
authors.affiliation: Singapore Institute for Clinical Sciences, ASTAR, Singapore.
authors.forename: Suresh Anand
authors.initials: SA
authors.lastname: Sadananthan
authors.affiliation: Laboratory of Molecular Imaging, Singapore Bioimaging Consortium, ASTAR, Singapore.
authors.forename: Venkatesh
authors.initials: V
authors.lastname: Gopalan
authors.affiliation: Takeda Singapore Pte. Ltd., Singapore.
authors.forename: Min-Li Sandra
authors.initials: ML
authors.lastname: Tan
authors.affiliation: Laboratory of Molecular Imaging, Singapore Bioimaging Consortium, ASTAR, Singapore.
authors.forename: Terry Yew
authors.initials: TY
authors.lastname: Keong
authors.affiliation: Takeda Singapore Pte. Ltd., Singapore.
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Zhou
authors.affiliation: Takeda Pharmaceutical Company Limited, Tokyo, Japan.
authors.forename: Seigo
authors.initials: S
authors.lastname: Ishino
authors.affiliation: Takeda Pharmaceutical Company Limited, Tokyo, Japan.
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Nakano
authors.affiliation: Takeda Pharmaceutical Company Limited, Tokyo, Japan.
authors.forename: Masanori
authors.initials: M
authors.lastname: Watanabe
authors.affiliation: Takeda Pharmaceutical Company Limited, Tokyo, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Horiguchi
authors.affiliation: Takeda Pharmaceutical Company Limited, Tokyo, Japan.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Nishimoto
authors.affiliation: Takeda Singapore Pte. Ltd., Singapore.
authors.forename: Bin
authors.initials: B
authors.lastname: Zhu
authors.affiliation: Laboratory of Molecular Imaging, Singapore Bioimaging Consortium, ASTAR, Singapore. ; Singapore Institute for Clinical Sciences, A*STAR, Singapore. ; Clinical Imaging Research Centre, NUS-A*STAR, Singapore.
authors.forename: S Sendhil
authors.initials: SS
authors.lastname: Velan
keywords: MRI; MRS; Sibutramine; calorie restriction; intramyocellular lipids; liver; obesity